First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
The AICVD tool can predict the risk of cardiovascular disease.
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
A total of 300 transgender individuals were screened as part of the study, with 82 identified as high-risk due to symptoms of anxiety, depression, and self-harm or suicidal tendencies
Subscribe To Our Newsletter & Stay Updated
